Current and Newsworthy Prostate Cancer Information You Need to Know

Jonathan McDermed, PharmD

Director, Scientific and Clinical Affairs
IRIS International, Inc., Molecular Diagnostics Division
Member, Us TOO HotSheet Editorial Team
Us TOO HotSheet

- 8-page monthly newsletter
  - “Burning Issues” supplements
- 3-member Editorial Team
  - Tom Kirk, President & CEO, Us TOO International
  - Pam Barrett, Us TOO Development Director
  - Jonathan McDermed, PharmD
- Includes announcements, upcoming & recent support group events, fundraising activities, patient vignettes, medical articles & information from 3 physician columns
Us TOO HotSheet

• Items in Us TOO publications are obtained from various news sources and are edited for inclusion

• Where available, contact information is provided (website, e-mail, phone number)

• References to persons, companies, products or services are provided for information only and are not endorsements

• Information and opinions expressed by Us TOO are not recommendations for any medical treatment, product, service or course of action
Basic goals of the Us TOO HotSheet

Inform

Educate

Offer hope
Sources of medical information

• News services
  - Reuters, Medscape, MedPage Today, Health Day, certain online newspapers, etc.

• Press releases
  - American Cancer Society (ACS), FDA, NCI, AUA, ASCO, ASTRO, universities, private companies

• Abstracts & journal articles
  - Some E-publications ahead of print

• Websites & blogs
There are many topics of interest

- Risk factors
  - Hereditary, other factors
- Prevention
  - Diet & lifestyle changes
  - Proscar, Avodart, etc.
- Early detection (PSA)
  - Screening controversy
- Diagnosis
  - Biopsies, imaging
  - First biopsy negative??
- Staging
  - Role of imaging
- Treatment options
  - Early stage disease
  - Biochemical recurrence
  - Distant spread ("mets")
    - Hormone responsive
    - Hormone refractory
- Investigational agents
  - Chemotherapy
  - Therapeutic vaccines
  - Biologic agents
    - Angiogenesis inhibitors
    - Monoclonal antibodies
- Supportive care
Medical information grows continually

- Each decade, the number of new papers related to prostate cancer doubles (x2)
- Focus before 1990 was epidemiology, testing, treatment options
- Focus now includes
  - PSA screening
  - Prevention
  - Genes (risk factors, etc.)
  - New tests, drugs, biologics
Doc Moyad’s “No Bogus Science”

• Co-director of the men's health program at the University of Michigan Medical Center

• Editor-in-chief of the journal “Seminars in Preventive & Alternative Medicine”

• Author of several books

• Areas of primary interest include
  - Prostate cancer
  - Cardiovascular diseases
  - Osteoporosis
  - Diet, exercise & nutritional supplements
Ask Dr. Snuffy Myers

- Medical oncologist specializing in prostate cancer providing comprehensive patient care
- Prostate cancer survivor
- Former cancer researcher at NIH
- Prostate Forum – educational arm of his practice
  - Monthly newsletter and hosts an interactive website
- Column addresses questions from survivors or significant others that are e-mailed to his website
- All topics are relevant to prostate cancer & address difficult or controversial topics
Dr. Chodak’s Bottom Line

• Provides comments regarding the medical articles appearing in each issue of the HotSheet & gives his “bottom line” conclusions & recommendations.

• Medical feedback is valuable to “balance” the information conveyed in some of the news releases.

• Emphasizes the need for studies to provide Level One evidence of safety & efficacy of any new treatment approach.
What medical articles do we print?

- All articles must be medically relevant
  - Studies of new drugs or medical procedures
  - Recently published medical articles
  - Policy statements (e.g., ACS, AUA, ASCO)
  - Clinical trials for certain prostate cancer groups

- Articles we like to avoid
  - Non-human studies (e.g., cells, animal studies)
  - Most phase I studies & many Phase II studies
  - Articles reporting data from the same study
  - Studies with results that are potentially biased
Information important to survivors

• Prostate cancer advocacy activities
  - Support group meetings
  - Special educational events
  - Fundraising activities
  - Reports from Board of Directors meetings

• New diagnostic tests and treatments
  - Prostate cancer risk assessment
  - Managing incontinence
  - Managing erectile dysfunction
Education

- Brochures
- Books
- CDs & tapes
- Us TOO University
New treatments that may offer Hope

- Abiraterone acetate
- Provenge
Abiraterone – for failure with primary ADT

Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy


Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "C" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: Thian Eeoh, Cougar Biotechnology (C); Arturo Molina, Cougar Biotechnology (C) Consultant or Advisory Role: Charles J. Ryan, Cougar Biotechnology (U); Matthew R. Smith, Cougar Biotechnology (U); Philip Kantoff, Cougar Biotechnology (C); Eric J. Small, Cougar Biotechnology (C) Stock Ownership: Thian Eeoh, Cougar Biotechnology; Arturo Molina, Cougar Biotechnology; Florence Raynaud, Cougar Biotechnology; Vanessa Martins, Cougar Biotechnology Expert Testimony: None Other Remuneration: None
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

Alison I.M. Reid, Chi-Hung A. Au, Toshinari Akiyama, David C. D'Amico, Nicholas D. Compton, David C. Gimm, Peter C. Dong, L. Rasha Mofleh, Joanne Hunt, Christina Messiou, Christopher Parker, David Doomsay, Joost F. Swennehoffs, Leen W.M.M. Verspuijen, Gauri Lee, Tilman Kiechel, Arturo Mactoma, Charles J. Ryan, Eric Tannal, Howard I. Scher, and Johann S. de Bono

Fig 1. Waterfall plots of prostate-specific antigen (PSA) changes. (A) Waterfall plot of greatest percentage change in PSA of individual patients on abiraterone acetate. (B) Waterfall plot of PSA change from baseline at 12 weeks for individual patients on abiraterone acetate. Brown, gold and gray lines indicate a decline in PSA of 30%, 50% and 90%, respectively. Some patients had a PSA decline on study but this was short-lived; PSA then increased again, which explains why the week-12 and maximal PSA declines are different.
Abiraterone - for docetaxel resistance

- PSA response (>50% decline) in 24/47 (51%) of patients
  - Average time to PSA progression 24 weeks
  - 12/47 (25.5%) still responding after 48 weeks

- Partial response (≤50% ↓ in tumor mass) in 8/30 (27%) patients

- Circulating tumor cell counts ↓ also
Provenge - for advanced disease

- 512 randomized to Provenge or placebo
- Relative risk of death ↓22% vs. the placebo
- Median survival ↑4.1-months (25.8 months with Provenge vs. 21.7 months with placebo)
- 3-year survival probability was 31.7% with Provenge vs. 23.0% with placebo
- PSA response had no relationship to survival
- The time to objective disease progression was similar in the two study groups
Try to avoid “false hope” at all costs

- Potential new drugs that weren’t effective in head-to-head comparison studies (Phase III)
  - Atrasentan (Xinlay®, Abbott)
  - Lycopene, selenium & vitamin E
  - Calcitriol (Asentar®, Novacea)
  - Satraplatin (Orplanta®, GPC Biotech)
  - GVAX (Cell Genesis)

- The jury is still out
  - MDV3100
  - OGX-0111
Summary & conclusions